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Abstract
Background: Phthalates, commonly used to soften plastic goods, are known PPAR-agonists affecting lipid
metabolism and adipocytes in the experimental setting. We evaluated if circulating concentrations of phthalates
were related to different indices of obesity using data from the Prospective Investigation of the Vasculature in
Uppsala Seniors (PIVUS) study. Data from both dual-energy X-ray absorptiometry (DXA) and abdominal magnetic
resonance imaging (MRI) were used.
Methods: 1,016 subjects aged 70 years were investigated in the PIVUS study. Four phthalate metabolites were
detected in the serum of almost all subjects (> 96%) by an API 4000 liquid chromatograph/tandem mass
spectrometer. Abdominal MRI was performed in a representative subsample of 287 subjects (28%), and a dual-
energy X-ray absorptiometry (DXA)-scan was obtained in 890 (88%) of the subjects two year following the
phthalate measurements.
Results: In women, circulating concentrations of mono-isobutyl phthalate (MiBP) were positively related to waist
circumference, total fat mass and trunk fat mass by DXA, as well as to subcutaneous adipose tissue by MRI
following adjustment for serum cholesterol and triglycerides, education, smoking and exercise habits (all p < 0.008).
Mono-methyl phthalate (MMP) concentrations were related to trunk fat mass and the trunk/leg-ratio by DXA, but
less powerful than MiBP. However, no such statistically significant relationships were seen in men.
Conclusions: The present evaluation shows that especially the phthalate metabolite MiBP was related to increased
fat amount in the subcutaneous abdominal region in women measured by DXA and MRI two years later.
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Background
Phthalates (phthalate diesters) are commonly used as
plasticisers in e.g. polyvinylchloride (PVC) plastics, and
are therefore found in numerous household products
such as food packaging, furniture, and toys; and in med-
ical devices such as tubing and intravenous bags. In
addition, phthalates are used in personal care products
and pharmaceuticals. Since phthalates are additives and
as such not covalently bound to the plastic, they can
easily leach and transfer to e.g. air and food. Humans
are exposed to phthalates through inhalation, ingestion,
and dermal exposure, and exposure is ubiquitous due to
the abundance of plastic in our society and in our
homes. Phthalates are rapidly degraded into the respec-
tive phthalate monoesters in phase I reactions catalysed
by lipases and esterases. The respective monoesters are
eliminated in the urine as glucuronide conjugates or are
further metabolised, and it is in fact the monoester
metabolites that have been claimed to be responsible for
adverse health effects [1-4].
Phthalates have been identified as endocrine-disrupt-
ing compounds (EDCs) with anti-androgenic effects on
the developing male reproductive system through
decreased testosterone biosynthesis [5,6]. Besides effects
on reproduction, increasing attention is now being
focused on the metabolic effects of phthalates and other
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prevalence of obesity and associated diseases such as
type 2 diabetes and cardiovascular diseases have risen
dramatically worldwide during the last decades [13], and
the search is on for explanations to complement the
main causes of high caloric intake combined with low
caloric expenditure, such as EDC exposure [11,14].
Several phthalate monoesters indeed bind to and acti-
vate the human peroxisome proliferator-activated recep-
tors (PPARs) [15,16]. PPAR gamma is involved in fat
storage by promoting adipocyte maturation and survival,
and also controls insulin sensitivity [17]. PPAR gamma
is targeted by the anti-diabetic thiazolidinedione drugs,
whose agonistic actions not only improve insulin sensi-
tivity but also promote weight gain [17,18]. Accordingly,
PPARs activation by MEHP and other phthalate monoe-
sters promotes the differentiation of both mouse and
human preadipocytes into adipocytes [15,16,19].
In the present study, we evaluated if human serum
phthalate monoester concentrations were related to dif-
ferent indices of obesity as determined using dual-
energy X-ray absorptiometry (DXA) combined with
abdominal magnetic resonance imaging (MRI). DXA
provides estimates of lean and fat mass from a frontal
whole-body scan, while the abdominal MRI employed
determines visceral and subcutaneous adipose tissue
areas in a single transversal section. Two previous stu-
dies have investigated the associations between urinary
phthalate monoester concentrations and obesity using
body mass index (BMI) and waist circumference (WC)
in US citizens [9,10]. However, this is to our knowledge
the first study on phthalate concentrations and obesity
using advanced technology measures, allowing analyses
of fat content in different body compartments (DXA), as
well as comparisons between visceral and subcutaneous
fat amount (MRI). We evaluated the hypothesis that
phthalates could alter the adipose tissue distribution
using measurements of fat distribution at MRI as our
p r i m a r ym e a s u r e m e n t .W ea l s os u p p l yd a t ao nm o r e
commonly used obesity measures and DXA derived
data.
Methods
Subjects
The study base for the PIVUS study (Prospective inves-
tigation of the vasculature in Uppsala seniors) were all
subjects aged 70 (standard deviation for age 1 month,
investigated 2001-2003) living in the community of
Uppsala, Sweden. The subjects were randomly chosen
from the register of community living. A total of 1,016
subjects participated, giving a participation rate of
50.1%. All women were postmenopausal. The study was
approved by the Ethics Committee of Uppsala
University.
All subjects were investigated in the morning after an
overnight fast, since phthalate concentrations and lipid
concentrations might change following a meal. No med-
ication or smoking was allowed after midnight. The sub-
jects were asked to answer a questionnaire about their
medical history, education level, exercise habits, smoking
habits, and regular medication. Education level was
divided into three groups: <9 years, 9-12 years, and >12
years. Exercise habits were divided into four groups: <2
times light exercise (no sweat) per week, ≥2t i m e sl i g h t
exercise per week, 1-2 times heavy exercise (sweat) per
week, and >2 times heavy exercise per week. Venous
blood samples were collected and stored at -70°C until
analysis of phthalate metabolites. Lipid variables were
measured the same day as the blood was drawn using
standard laboratory techniques. Basic characteristics of
subjects are given in Table 1.
Phthalate analysis
Human serum (0.5 ml) was analysed for concentrations
of ten phthalate metabolites by an API 4000 liquid chro-
matograph/tandem mass spectrometer at ALS Canada
following the general procedures presented by the Cen-
ters for Disease Control and Prevention and as pre-
viously described [20]. Briefly, quality control of the
analyses was maintained by analysing a method blank
(calf serum) and two spiked calf serum samples (20 ng/
ml, all analytes) along with every 17 samples. The detec-
tion limits (LOD), was 0.2 ng/ml. Four out of the ten
phthalate metabolites, namely mono-(2-ethylhexyl)
phthalate (MEHP); mono-ethyl phthalate (MEP); mono-
isobutyl phthalate (MiBP); and mono-methyl phthalate
(MMP), were detectable in all but 5-12 subjects (at least
96% of subjects). The fact that some subjects showed
undetectable concentrations rules out a general contam-
ination of these compounds. Only the four metabolites
with detectable concentrations were used in the statisti-
cal analysis. For the rest of the metabolites, 31-100% of
the observations were below the detection limit. The
measured serum concentrations of MEHP, MEP, MiBP,
and MMP are given in Table 1. The analysis of the
phthalates took place 5-8 years following collection of
the samples.
Fat mass analysis by DXA
On average two years after the investigation at age 70
when data on phthalate metabolites were collected all
subjects were invited to an investigation with dual-
energy X-ray absorptiometry (DXA) (DPX, Lunar Prod-
igy, Lunar Corp., Madison, WI, USA), with the primary
outcome total body fat mass. Of the original sample,
890 subjects (88% of subjects investigated at baseline)
participated in this part of the study. Since abdominal
fat repeatedly has been shown to be more harmful than
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secondary outcome, whether concentrations of phthalate
metabolites were more closely related to trunk fat mass,
defined as fat between the groins and the shoulders, or
to leg fat mass, defined as fat below the groins.
In order to evaluate the reproducibility, fifteen sub-
jects were scanned three times. The precision error of
the DXA measurements was calculated to be 1.5% for
total fat mass and 1.0% for total lean mass [22]. The
bias associated with DXA fat measurement is systematic,
with an underestimation of fat content for leaner sub-
jects and an overestimation of fat content among obese
subjects, but these inaccuracies amount to less than
2% [23].
Abdominal MRI
Also magnetic resonance imaging (MRI) of the abdom-
inal region was performed in 287 randomly selected
subjects from the PIVUS cohort on average two years
after the investigation at age 70 when data on phthalate
metabolites were collected. Only a restricted sample
could be offered this examination for financial reasons.
Visceral and subcutaneous adipose tissue areas (cm
2)
(VAT and SAT, respectively) were manually segmented
from a single 10 mm thick axial steady-state-free preces-
sion slice as previously described [24]. Based on
repeated measurements of VAT and SAT in 22 subjects,
the reproducibility/coefficients of variation (CVs) were
found to be 5.9 and 3.4%, respectively.
Since the DXA and MRI scan measurements are not
affected by a single over-night fast, these investigations
were performed in the non-fasted state.
Statistical analysis
All variables were evaluated regarding non-normality,
and variables with a skewed distribution, such as plasma
triglycerides and phthalate metabolite concentrations,
were ln-transformed. In separate linear regression mod-
els for each phthalate metabolite and each gender, the
phthalate metabolite concentrations (as ln-transformed
continuous variables) were related to indices of obesity,
as well as to fat mass measurements by DXA and
abdominal MRI. In each model we adjusted for serum
cholesterol and triglycerides, education, exercise, and
smoking. In order to use the full power of the study, all
subjects who had an obesity outcome measured were
included in that particular model. The phthalate meta-
bolites were also divided into quintiles to evaluate
potential non-linear relationships, using both a linear
and a quadratic term. For our primary hypothesis that
the 4 phthalates were related to the two MRI measure-
ments in both men and women, we adjusted the p-value
Table 1 Basic characteristics of subjects
Women Men
Variable N Mean (SD) Median (25
th and
75
th percentile)
N Mean (SD) Median (25
th and
75
th percentile)
BMI (kg/m
2) 509 27.1 (4.9) 26.5 (23.7, 30.1) 507 27 (3.7) 26.8 (24.4, 29.1)
Waist (cm) 503 87.6 (11.6) 87.0 (79.0, 94.0) 501 94.7 (10.4) 94.0 (87.0, 101.0)
Waist/hip ratio 503 0.90 (0.10) 0.90 (0.80, 0.90) 501 0.90 (0.10) 0.9 (0.9, 1.0)
DXA total fat (kg) 459 27.7 (9.2) 27.1 (21.1, 33.7) 431 23.5 (8.2) 22.5 (17.6, 28.4)
DXA leg fat (kg) 459 9.7 (3.4) 9.4 (7.2, 11.8) 431 6.3 (2.6) 5.9 (4.7, 7.5)
DXA trunk fat (kg) 459 13.9 (5.0) 13.8 (10.2, 17.4) 431 14.1 (5.1) 13.8 (10.5, 17.5)
DXA trunk/leg ratio 459 1.5 (0.4) 1.4 (1.2, 1.7) 431 2.3 (0.6) 2.3 (1.9, 2.6)
MRI SAT (cm
2) 139 262.1 (108.9) 257.4 (190.9, 313.9) 148 189.0 (80.3) 172.8 (131.3, 231.7)
MRI VAT (cm
2) 139 94.3 (49.1) 87.5 (58.5, 119.2) 148 119.3 (63.0) 102.4 (79.2, 151.9)
MRI VAT/SAT ratio 139 0.4 (0.2) 0.3 (0.2, 0.5) 148 0.6 (0.3) 0.6 (0.5, 0.8)
MEHP (ng/ml) 502 18.9 (42.5) 4.7 (2.0, 14.5) 501 20.3 (45.0) 4.3 (2.1, 17.4)
MEP (ng/ml) 502 14.0 (10.3) 11.6 (7.2, 16.8) 501 18.0 (21.1) 11.6 (7.2, 18.5)
MiBP (ng(ml) 502 44.6 (116) 13.4 (9.5, 24.5) 501 53.6 (146.1) 13.5 (9.1, 33.3)
MMP (ng/ml) 502 3.4 (5.1) 1.5 (0.9, 3.0) 501 3.3 (4.5) 1.5 (0.8, 3.2)
Current smoking (%) 509 11.4 506 9.9
Serum cholesterol (mmol/l) 507 5.7 (1.0) 5.7 (5.0, 6.3) 506 5.1 (1.0) 5.1 (4.5, 5.8)
Serum triglycerides (mmol/l) 508 1.3 (0.6) 1.1 (0.9, 1.5) 505 1.3 (0.6) 1.2 (0.9, 1.5)
Mean (SD) and median (25th and 75th percentile) given for the studied variables in women and men. The DXA and MRI measurements were performed two year
following the measurements of phthalate metabolites and other measurements presented in the table
BMI-Body mass index; DXA-Dual-energy X-ray absorptiometry; MEHP-Mono-(2-ethylhexyl) phthalate; MEP-Mono-ethyl phthalate; MiBP-Mono-isobutyl phthalate;
MMP-Mono-methyl phthalate; MRI-Magnetic resonance imaging; SAT-Subcutaneous adipose tissue; VAT-Visceral adipose tissue
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0.003125).
STATA 11 (College Station, TX, USA) was used for
calculations.
Results
Basic characteristics
The basic characteristics of subjects and the serum con-
centrations of the four phthalate metabolites are pre-
sented in Table 1 as mean values (standard deviations),
and as median concentrations (25
th and 75
th percentiles)
in the total sample. No significant differences were seen
in the subsample with DXA measurements, or in the
subsample with MRI scans, when compared with the
total sample.
Linear regression analysis with continuous variable
The results from the linear regression analyses using cir-
culating concentrations of phthalate metabolites as con-
tinuous variables are presented in Table 2 for women
and in Table 3 for men. The results were adjusted for
fasting serum cholesterol and triglycerides, education,
smoking and exercise habits. In women, circulating con-
centrations of MiBP were positively related to WC, total
fat mass and trunk fat mass by DXA, as well as to SAT
by MRI (Table 2 all p < 0.008).
The relationship between MiBP and SAT at MRI shows
a p-value below the critical p-value obtained after correc-
tion for multiple testing. MMP concentrations in women
were positively related to trunk fat mass and to trunk/
leg-ratio by DXA (Table 2 both p < 0.01). However, no
such significant relationships were seen in women for
MEHP or MEP (Table 2), and no significant relationships
were found in men for either metabolite (Table 3).
According to the regression models, a doubling of the
MiBP concentrations corresponded to an increase of 45
cm
2 in SAT at MRI, 0.8 kg in trunk fat mass at DXA,
and 1.5 cm in waist circumference in women. The cor-
responding effects of a doubling of MMP were 35 cm
2
in SAT at MRI, 0.4 kg in trunk fat at DXA, and 0.8 cm
in waist circumference in women.
Quintile analysis
The results from the quintile analysis approach are pre-
sented in Additional file 1: Tables S1-S8. Quintile analy-
sis showed the same linear relationships for MiBP in
women as described above using continuous data. In
addition, positive linear relations were found between
MEP and DXA trunk/leg ratio, as well as between MMP
and WC and waist/hip ratio, all in men. Furthermore,
t h eq u i n t i l ea n a l y s i ss h o w e d U-shaped relationships
between MEP and SAT by MRI in women (p =0 . 0 0 9 8 ) ,
as well as between MiBP and waist/hip-ratio in men (p
= 0.0011).
Since there is some bias in the DXA estimations
regarding fat mass (see methods section), we performed
a secondary analysis in which the fat mass values for the
lean subjects (BMI < 25 kg/m
2) were multiplied by 1.02,
a n db y0 . 9 8i nt h eo b e s e( B M I>3 0k g / m
2). This
attempt to compensate for the bias introduced by the
DXA technique did however only have marginally
effects on the analysis presented above.
Discussion
The present study showed that serum concentrations of
the phthalate metabolites MiBP and MMP were posi-
tively correlated to several obesity indices in women. In
particular, a strong positive relation was found between
Table 2 Relationships between four phthalate metabolites and markers of obesity in women
MEHP MEP MiBP MMP
Variable n Beta (95% CI) p-value Beta (95% CI) p-value Beta (95% CI) p-value Beta (95% CI) p-value
BMI (kg/m
2) 479 0.10 (-0.20-0.41) 0.51 0.008 (-0.67-0.69) 0.98 0.39 (0.002-0.79) 0.049 0.28 (-0.095-0.66) 0.14
Waist (cm) 474 0.34 (-0.39-1.1) 0.36 -0.80 (-2.4-0.81) 0.33 1.3 (0.425-2.3) 0.0043 0.98 (0.090-1.9) 0.031
Waist/hip ratio 474 0.002 (-0.002-0.006) 0.24 -0.008 (-0.016-0.001) 0.086 0.004 (0.000-0.009) 0.079 0.005 (0.000-0.009) 0.051
DXA total fat (kg) 431 468 (-159-1096) 0.14 -469 (-1877-938) 0.51 1079 (283-1875) 0.0082 705 (-74-1484) 0.077
DXA leg fat (kg) 431 163 (-73-399) 0.18 -165 (-694-363) 0.54 275 (-25-576) 0.0733 115 (-179-409) 0.44
DXA trunk fat (kg) 431 206 (-127-539) 0.23 -187 (-934-559) 0.62 699 (279-1120) 0.0012 546 (135-958) 0.0096
DXA trunk/leg ratio 431 -0.007 (-0.033-0.019) 0.60 -0.004 (-0.062-0.054) 0.88 0.039 (0.006-0.072) 0.021 0.043 (0.011-0.075) 0.0082
MRI SAT (cm
2) 135 4.8 (-10-20) 0.53 12 (-24-48) 0.51 52 (24-81) 0.0004 27 (3.1-52) 0.029
MRI VAT (cm
2) 135 4.1 (-2.2-10) 0.20 3.6 (-11-19) 0.63 14 (1.4-26) 0.031 6.9 (-3.4-17) 0.19
MRI VAT/SAT ratio 135 0.005 (-0.018-0.028) 0.67 -0.001 (-0.056-0.054) 0.96 -0.018 (-0.064-0.028) 0.45 -0.019 (-0.057-0.019) 0.34
Shown are results from linear regression models adjusting for serum cholesterol and triglycerides, education, exercise and smoking. The number of subjects used
in the models for the different obesity outcome measurements are given as n. The units for the different obesity measures are given in table 1. The phthalate
metabolites are given in ng/ml and ln-transformed values are used in the analysis
BMI-Body mass index; DXA-Dual-energy X-ray absorptiometry; MEHP-Mono-(2-ethylhexyl) phthalate; MEP-Mono-ethyl phthalate; MiBP-Mono-isobutyl phthalate;
MMP-Mono-methyl phthalate; MRI-Magnetic resonance imaging; SAT-Subcutaneous adipose tissue; VAT-Visceral adipose tissue
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cutaneous adipose tissue measured by DXA and MRI
two years following the phthalate measurements were
performed.
Strengths of the study
Our study employed a hitherto unique combination of
dual-energy X-ray absorptiometry (DXA) and abdominal
magnetic resonance imaging (MRI), while previous stu-
dies of the relationship between phthalate concentra-
tions and obesity have been limited to the use of body
mass index (BMI) and waist circumference (WC) [9,10].
Our approach combining DXA and abdominal MRI
offers a whole new level of resolution and specificity to
different aspects of obesity, in particular the distinction
between visceral and subcutaneous adipose tissue, both
as an MRI VAT/SAT ratio and as a DXA trunk/leg fat
ratio. Furthermore, if we find a relationship between a
phthalate metabolite and similar obesity measurements
both at DXA and MRI, that will reduce the chance of
false positive findings.
Both previous studies of phthalate concentrations in
relation to obesity were based on data from the US
National Health and Nutrition Examination Survey
(NHANES) [9,10]. Neither study included MiBP or
MMP. Stahlhut et al found positive associations between
MEP concentrations and WC in men over 18 years of
age [10], while Hatch et al found mixed associations
between MEP/MEHP and BMI in women and men of
different age groups [9]. Hatch et al also found negative
relations between MEHP urine concentrations and BMI
in both women and men aged 60-80 years [9], which
was not observed in our subjects. The advantage with
t h eP I V U Ss t u d yc o m p a r e dt oN H A N E Si st h a tw e
could characterize obesity in more detail by regional dis-
tribution of fat mass by DXA and MRI.
Limitations of the study
Two limitations in the present study related to the DXA
and MRI measurements are that these examinations
were performed two years following the measurements
of the phthalates, and the fact that not all subjects inves-
tigated at baseline were investigated with the two ima-
ging techniques. Regarding the time lag between the
phthalate measurements and the imaging, this could
lead to false negative results since both changes in
phthalates and obesity measures could have occurred
during the two year period that might have influenced
the investigated relationships. However, it is very unli-
kely that the reported main finding that MiBP concen-
trations are related to trunk fat at DXA and to SAT at
MRI could be created by a time lag. The fact that MiBP
concentrations also were related to waist circumference,
measured at the same day as MiBP, further strengthens
t h ec a s et h a tt h em a i nf i n d i n g si nt h ep r e s e n ts t u d ya r e
not erroneously created by this time lag. However, only
a true longitudinal study with serial evaluations with
DXA and MRI will clarify this issue.
The fact that a time lag of two years will create a
selection of survivors and a drop-out of subjects not
willing to be reinvestigated is undisputed. We do not
think that this selection of subjects attending the ima-
ging procedures will introduce any major bias that will
influence the results since all basic characteristics were
essentially the same in the total sample and the subsam-
ples attending the DXA and MRI scans.
In the present study we used serum measurements of
phthalate metabolites. It is more common to use urinary
Table 3 Relationships between four phthalate metabolites and markers of obesity in men
MEHP MEP MiBP MMP
Variable n Beta(95% CI) p-value Beta (95% CI) p-value Beta (95% CI) p-value Beta (95% CI) p-value
BMI (kg/m
2) 482 -0.034 (-0.26-0.19) 0.77 0.31 (-0.097-0.72) 0.14 -0.083 (-0.35-0.19) 0.55 0.33 (0.051-0.61) 0.021
Waist (cm) 478 -0.27 (-0.91-0.37) 0.41 0.73 (-0.45-1.9) 0.22 -0.025 (-0.80-0.75) 0.95 0.97 (0.17-1.78) 0.0175
Waist/hip ratio 478 -0.004 (-0.008-0.0) 0.044 0.005 (-0.003-0.012) 0.22 0.001 (-0.004-0.005) 0.81 0.006 (0.001-0.011) 0.024
DXA total fat (kg) 410 12 (-527-552) 0.96 269 (-776-1315) 0.61 -73 (-754-608) 0.83 365 (-340-1071) 0.31
DXA leg fat (kg) 410 -24 (-200-152) 0.79 46 (-296-388) 0.79 -44 (-266-179) 0.70 37 (-194-268) 0.75
DXA trunk fat (kg) 410 0.56 (-332-333) 0.9974 347 (-297-991) 0.29 -23 (-443-398) 0.92 235 (-201-670) 0.29
DXA trunk/leg ratio 410 -0.008 (-0.048-0.033) 0.71 0.095 (0.018-0.17) 0.016 0.007 (-0.044-0.058) 0.78 0.021 (-0.031-0.074) 0.43
MRI SAT (cm
2) 144 0.44 (-9.6-10) 0.93 9.2 (-10-29) 0.36 -11 (-34-12) 0.34 5.4 (-7.9-19) 0.43
MRI VAT (cm
2) 144 3.3 (-4.9-11) 0.43 16 (0.49-32) 0.045 -5.9 (-24-13) 0.54 5.2 (-5.7-16) 0.35
MRI VAT/SAT ratio 144 0.002 (-0.032-0.036) 0.91 0.052 (-0.013-0.12) 0.12 0.001 (-0.076-0.079) 0.98 0.003 (-0.043-0.048) 0.91
Shown are results from linear regression models adjusting for serum cholesterol and triglycerides, education, exercise and smoking. The number of subjects used
in the models for the different obesity outcome measurements are given as n. The units for the different obesity measures are given in table 1. The phthalate
metabolites are given in ng/ml and ln-transformed values are used in the analysis
BMI-Body mass index; DXA-Dual-energy X-ray absorptiometry; MEHP-Mono-(2-ethylhexyl) phthalate; MEP-Mono-ethyl phthalate; MiBP-Mono-isobutyl phthalate;
MMP-Mono-methyl phthalate; MRI-Magnetic resonance imaging; SAT-Subcutaneous adipose tissue; VAT-Visceral adipose tissue
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is that usually higher concentrations are found com-
pared to serum and thereby more phthalate metabolites
could be quantified above the lower detection limit.
Therefore we can only report associations regarding
four metabolites, although in fact 10 metabolites were
evaluated. Serum concentrations might also change
more rapidly than urinary concentrations, and therefore
repeated measurements would be desirable for a more
precise measure of exposure.
The participating subjects were all elderly (aged 70)
Caucasians, which obviously confers limitations as to
the applicability of the results with respect to the gen-
eral population. For example, Hatch et al found large
differences in associations between urine concentra-
tions of phthalate metabolites and obesity depending
on age group [9], and Stahlhut et al observed differ-
ences between ethnic groups [10]. On the other hand,
the relative homogeneity and large number of subjects
permit the detection of more subtle effects. Moreover,
the age of our subjects isolates the effects of adult
exposure and precludes any effects from gestational
and perinatal phthalate exposure since these chemicals
were not in use when the subjects were born. Further-
more, the populations in Europe and US are steadily
increasing in age and therefore it is of importance to
study the effect of exposure to environmental contami-
nants not only in the newborn, but also in the aged
population.
Gender differences and possible mechanisms
In this study, circulating concentrations of MiBP were
positively related to several obesity indices in women,
most notably trunk fat by DXA and SAT by MRI, while
no such associations were seen in men. This gender dif-
ference is particularly interesting since no significant dif-
ferences in phthalate metabolite concentrations were
found between men and women in this material [25].
The differences in effects thus cannot be attributed to
differences in phthalate concentrations, but may instead
reflect gender-specific regulation of adipose tissue distri-
bution. Using BMI and WC, Hatch et al found no gen-
der differences in subjects aged 60-80 years [9],
reflecting the higher precision of our DXA/MRI
approach.
Several studies have described a cross-talk between
estrogen or estrogen receptors and activation of PPAR
receptors, the most well characterized target for the
phthalates [26-28]. Ovariectomized rats treated with a
PPAR alpha agonist showed a less pronounced increase
in fat mass. This condition was reversed by estrogen
treatment, which also reduced PPAR alpha expression
[28]. Similarly, overiectomized mice treated with a
PPAR gamma agonist showed a less pronounced
increase in fat mass. Also this condition was reversed by
estrogen treatment, which also reduced PPAR gamma
expression [26]. Ovariectomy increased fat tissue in
mice compared to sham-operated controls. This effect
was inhibited in mice lacking the PPAR alpha gene [16].
Thus, if these experimental data suggesting a cross-talk
between PPAR receptor activation and estrogen are
similar in humans they may explain why activators of
PPARs, such as phthalates, could have different effects
in men and women.
As noted in the introduction, several phthalate
monoesters have been identified as PPAR gamma ago-
nists and capable of promoting adipocyte maturation,
providing a plausible mechanistic link to phthalate
effects on obesity development and adipose tissue distri-
bution [8,15,16,19]. To our knowledge, MiBP has not
been tested for PPAR activation, however MMP was
found not to activate either PPAR alpha or PPAR
gamma [16].
Statistical considerations
Some non-linear relationships were noted in the quintile
analysis, including some relationships in men. Non-
monotonic relationships have been previously described
for endocrine disruptors [29,30], however in this case
the non-linear relationships were seen only for certain
phthalates and certain obesity phenotypes, while MiBP
was related to many obesity phenotypes in women in a
consistent manner. The non-linear relationships
described in the present study must thus be interpreted
with caution.
In the present study, several statistical tests were per-
formed and this could lead to false positive results due
to multiple testing. However, regarding our primary
hypothesis that the four phthalates were related to fat
distribution measures at MRI a strict Bonferroni correc-
tion was used and when applying this MiBP was found
to be related to SAT in women. All other tests were
performed to seek for consistency between different
obesity measures and are therefore not subjected to any
adjustment for multiple testing. These results must
therefore be taken with caution, but as could be seen
these results fits well with findings regarding the pri-
mary hypothesis.
In the study we had outcome measures with variable
number of observations, only one third as many MRI
scans as DXA scans. Thus, when interpreting the p-
values it must be kept in mind that an association has
to be considerable stronger for a phthalate metabolite vs
an obesity measured at MRI than vs an obesity measure
at DXA to obtain a significant p-value. It is however not
reasonable to delete two thirds of the entire sample
from the calculations in order to make the p-values
comparable, since that approach will induce false
Lind et al. Environmental Health 2012, 11:21
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Page 6 of 8negative findings regarding the relationships between
phthalate concentrations and obesity measurements at
DXA.
Conclusions
The present evaluation shows that especially the phtha-
late metabolite MiBP was related to increased fat
amount in the subcutaneous abdominal region in
women measured by DXA and MRI two years later.
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